Upcyte Human Hepatocytes: A Potent in Vitro Tool for the Prediction of Hepatic Clearance of Metabolically Stable Compounds s

Drug Metabolism and Disposition

Volumn 44, Issue 3, 2016, Pages 435-444

  Schaefer, Michelle ^a   Schänzle, Gerhard ^a   Bischoff, Daniel ^a   Süssmuth, Roderich D ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; SULFOTRANSFERASE;

ARTICLE; CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATIC CLEARANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPCYTE HUMAN HEPATOCYTE; ADULT; DRUG INACTIVATION; KINETICS; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADULT; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; INACTIVATION, METABOLIC; KINETICS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; YOUNG ADULT;

EID: 84959018459     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.067348     Document Type: Article

References (59)

1. Andersson TB, Kanebratt KP, and Kenna JG (2012) The HepaRG cell line: A unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 8:909-920.
2. Blanchard N, Hewitt NJ, Silber P, Jones H, Coassolo P, and Lavé T (2006) Prediction of hepatic clearance using cryopreserved human hepatocytes: A comparison of serum and serum-free incubations. J Pharm Pharmacol 58:633-641.
3. Blanchard N, Richert L, Notter B, Delobel F, David P, Coassolo P, and Lavé T (2004) Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur J Pharm Sci 23:189-199.
4. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
5. Burkard A, Dähn C, Heinz S, Zutavern A, Sonntag-Buck V, Maltman D, Przyborski S, Hewitt NJ, and Braspenning J (2012) Generation of proliferating human hepatocytes using Upcyte® technology: Characterisation and applications in induction and cytotoxicity assays. Xenobiotica 42:939-956.
6. Chan TS, Yu H, Moore A, Khetani SR, and Tweedie D (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024-2032.
7. Chang M, Tybring G, Dahl ML, and Lindh JD (2014) Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: A systematic review and meta-analysis. Clin Pharmacokinet 53:801-811.
8. Chao P, Barminko J, Novik E, Han Y, Maguire T, and Cheng KC (2009) Prediction of human hepatic clearance using an in vitro plated hepatocyte clearance model. Drug Metab Lett 3: 296-307.
9. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
10. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, and Gilissen RA (2007) Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780.
11. Di L, Atkinson K, Orozco CC, Funk C, Zhang H, McDonald TS, Tan B, Lin J, Chang C, and Obach RS (2013) In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method. Drug Metab Dispos 41:2018-2023.
12. Di L and Obach RS (2015) Addressing the challenges of low clearance in drug research. AAPS J 17:352-357.
13. Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford AC, Tan B, McDonald TS, Lai Y, and Tremaine LM (2012) A novel relay method for determining low-clearance values. Drug Metab Dispos 40:1860-1865.
14. Donato MT, Jover R, and Gómez-Lechón MJ (2013) Hepatic cell lines for drug hepatotoxicity testing: Limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab 14:946-968.
15. Dunn JC, Tompkins RG, and Yarmush ML (1991) Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog 7:237-245.
16. Gebhardt R, Hengstler JG, Müller D, Glöckner R, Buenning P, Laube B, Schmelzer E, Ullrich M, Utesch D, and Hewitt N, et al. (2003) New hepatocyte in vitro systems for drug metabolism: Metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35:145-213.
17. Gómez-Lechón MJ, Donato MT, Castell JV, and Jover R (2004) Human hepatocytes in primary culture: The choice to investigate drug metabolism in man. Curr Drug Metab 5:443-462.
18. Gómez-Lechón MJ, Tolosa L, Conde I, and Donato MT (2014) Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol 10:1553-1568.
19. Griffin SJ and Houston JB (2005) Prediction of in vitro intrinsic clearance from hepatocytes: Comparison of suspensions and monolayer cultures. Drug Metab Dispos 33:115-120.
20. Guguen-Guillouzo C and Guillouzo A (2010) General review on in vitro hepatocyte models and their applications. Methods Mol Biol 640:1-40.
21. Guo L, Dial S, Shi L, Branham W, Liu J, Fang JL, Green B, Deng H, Kaput J, and Ning B (2011) Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos 39:528-538.
22. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: Retrospective analysis and prospective view. Pharm Res 27:2150-2161.
23. Hallifax D and Houston JB (2012) Evaluation of hepatic clearance prediction using in vitro data: Emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. J Pharm Sci 101:2645-2652.
24. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, and Skonberg C, et al. (2007) Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
25. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
26. Hutzler JM, Ring BJ, and Anderson SR (2015) Low-turnover drug molecules: A current challenge for drug metabolism scientists. Drug Metab Dispos 43:1917-1928.
27. Ito K and Houston JB (2004) Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 21: 785-792.
28. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112.
29. Kanebratt KP and Andersson TB (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444-1452.
30. Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126.
31. Lavé T, Chapman K, Goldsmith P, and Rowland M (2009) Human clearance prediction: Shifting the paradigm. Expert Opin Drug Metab Toxicol 5:1039-1048.
32. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188.
33. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
34. LeCluyse EL, Bullock PL, and Parkinson A (1996) Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Adv Drug Deliv Rev 22:133-189.
35. Levy G, Bomze D, Heinz S, Ramachandran SD, Noerenberg A, Cohen M, Shibolet O, Sklan E, Braspenning J, and Nahmias Y (2015) Long-term culture and expansion of primary human hepatocytes. Nat Biotechnol 33:1264-1271. 10.1038/nbt.3377.
36. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
37. Novik E, Maguire TJ, Chao P, Cheng KC, and Yarmush ML (2010) A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 79:1036-1044.
38. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
39. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
40. Poulin P, Kenny JR, Hop CE, and Haddad S (2012) In vitro-in vivo extrapolation of clearance: Modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J Pharm Sci 101:838-851.
41. Ramsden D, Tweedie DJ, Chan TS, Taub ME, and Li Y (2014a) Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab Dispos 42:394-406.
42. Ramsden D, Tweedie DJ, St George R, Chen LZ, and Li Y (2014b) Generating an in vitro-in vivo correlation for metabolism and liver enrichment of a hepatitis C virus drug, faldaprevir, using a rat hepatocyte model (HepatoPac). Drug Metab Dispos 42:407-414.
43. Richert L, Liguori MJ, Abadie C, Heyd B, Mantion G, Halkic N, and Waring JF (2006) Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos 34:870-879.
44. Richert L, Tuschl G, Abadie C, Blanchard N, Pekthong D, Mantion G, Weber JC, and Mueller SO (2009) Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol 235:86-96.
45. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
46. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, and He H, et al. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. J Pharm Sci 100:4090-4110.
47. Ring BJ, Gillespie JS, Eckstein JA, and Wrighton SA (2002) Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30:319-323.
48. Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, Sakamoto A, Ishiguro N, Matsumaru T, and Terasaki T, et al. (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 40:93-103.
49. Schmittgen TD and Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108.
50. Shibata Y, Takahashi H, Chiba M, and Ishii Y (2002) Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metab Dispos 30:892-896.
51. Skett P (1994) Problems in using isolated and cultured hepatocytes for xenobiotic metabolism/metabolism-based toxicity testing: Solutions? Toxicol In Vitro 8:491-504.
52. Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, and Sahi J (2012) A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. J Pharm Sci 101:3989-4002.
53. Sohlenius-Sternbeck AK, Afzelius L, Prusis P, Neelissen J, Hoogstraate J, Johansson J, Floby E, Bengtsson A, Gissberg O, and Sternbeck J, et al. (2010) Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637-649.
54. Su T and Waxman DJ (2004) Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. Arch Biochem Biophys 424: 226-234.
55. Tang H, Hussain A, Leal M, Mayersohn M, and Fluhler E (2007) Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886-1893.
56. Thummel K, Shen D, and Isoherranen N (2011) Goodman and Gilman's Pharmacological Basis of Therapeutics, McGraw Hill, New York.
57. Treijtel N, Barendregt A, Freidig AP, Blaauboer BJ, and Van Eijkeren JC (2004) Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutamide determined in sandwich-cultured rat hepatocytes. Drug Metab Dispos 32:884-891.
58. Wang WW, Khetani SR, Krzyzewski S, Duignan DB, and Obach RS (2010) Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 38:1900-1905.
59. Zuegge J, Schneider G, Coassolo P, and Lavé T (2001) Prediction of hepatic metabolic clearance: Comparison and assessment of prediction models. Clin Pharmacokinet 40:553-563.